Early Market Access Vehicle for VISITECT® CD4 Advanced Disease Test
The Early Market Access Vehicle (EMAV) is the first phase of a two-phased strategy designed by Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) to enable expanded access to the VISITECT® CD4 Advanced Disease test. Through the EMAV, selected implementing partners can qualify for Unitaid-funded procurement of VISITECT® CD4 Advanced Disease tests to facilitate evidence generation and user experience to inform future national implementation and planning and support routine use of the test.
Beginning on April 28, 2020, CHAI and Unitaid will begin accepting Expressions of Interest (EOI) and admitting selected partners to the EMAV on a rolling basis through September 30, 2021 (or when maximum volume commitment is delivered).
Interested partners should review the EOI or reach out to email@example.com for more information.Download the EOI now